BioNTech (NASDAQ:BNTX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $150.00 price target on the stock.

Other equities analysts have also issued research reports about the company. TD Cowen lowered their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. HSBC increased their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and increased their target price for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $138.79.

BioNTech Stock Performance

BNTX opened at $108.20 on Monday. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The stock has a market cap of $25.94 billion, a price-to-earnings ratio of -51.52 and a beta of 0.26. The business has a 50 day moving average of $113.80 and a 200-day moving average of $97.56. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period last year, the firm posted $0.73 earnings per share. The business’s revenue was up 38.9% on a year-over-year basis. On average, equities research analysts expect that BioNTech will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the last quarter. Covestor Ltd raised its position in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares in the last quarter. Capital International Sarl raised its position in shares of BioNTech by 1.3% in the 1st quarter. Capital International Sarl now owns 24,058 shares of the company’s stock worth $2,219,000 after acquiring an additional 310 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.